Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Ann Surg. 2020 Apr;271(4):716–723. doi: 10.1097/SLA.0000000000003051

TABLE 1.

Patient and Treatment Characteristics (N = 5086)

Characteristic No. (% or Range)
Demographics
 Sex
  Male 3100 (61)
  Female 1986 (39)
 Age
  Median  59 (19-90)
  <60 1743 (53.1)
  ≥60 1537 (46.9)
 Race
  White 4369 (85.9)
  African American 412 (8.1)
  Other/unknown 305 (6.0)
 Comorbidity score
  0 4029 (59.8)
  1 829 (16.3)
  2+ 228 (4.5)
 Insurance
  Not insured 226 (4.4)
  Private 2849 (56.0)
  Government 1953 (38.4)
 Treatment facility type
  Community cancer program 295 (5.8)
  Academic/research program 1917 (37.7)
  Comprehensive cancer program/other 2874 (56.5)
 Treatment facility location
  Metro counties 4098 (82.3)
  Urban counties 794 (15.9)
  Rural counties 88 (1.8)
 Income, US dollars
  <48,000 2012 (39.7)
  ≥48,000 3059 (60.3)
 Distance to treatment facility, miles
  ≤10 2391 (47.0)
  >10 2679 (52.7)
 Location
  East 1944 (38.2)
  Central 1913 (37.6)
  West 870 (17.1)
 Year of diagnosis
  2010–2011 1105 (21.7)
  2012–2013 1702 (33.5)
  2014–2015 2279 (44.8)
Disease characteristics
 Clinical T stage
  T1/T2 317 (6.2)
  T3 4312 (84.8)
  T4 428 (8.4)
 Clinical T size
  <2 cm 724 (14.2)
  2–5 cm 2517 (49.5)
  >5 cm 1237 (24.3)
 Clinical N stage
  N0 2026 (39.8)
  N1 2408 (47.3)
  N2 607 (11.9)
 Grade
  Well differentiated 403 (7.9)
  Moderately differentiated 3533 (69.5)
  Poorly differentiated 537 (10.6)
 Microsatellite instability
  Negative (stable) 4450 (87.5)
  Positive (instable) 636 (12.5)
Treatment characteristics
 Radiation dose, Gy
  Median (Gy)   50.4 (40.4–70.2)
  <50.4 769 (15.1)
  ≥50.4 and <54 3754 (73.8)
  ≥54 563 (11.1)
 Time from XRT to surgery
  ≤2 mos 2679 (52.7)
  2–4mos 2407 (47.3)
 Preoperative chemotherapy
  Single agent 2850 (56.0)
  Double agent 2088 (41.1)
  Unknown 148 (2.9)

Note: If sum of percentages is <100, then the remaining data are missing/unreported. Gy, gray.